Torrent Pharmaceuticals received final listing approval for 4.19 crore equity shares on NSE and BSE. These shares were issued to J. B. Chemicals & Pharmaceuticals shareholders as part of their amalgamation. Trading begins July 28, 2026.
Detailed Coverage
Torrent Pharmaceuticals Secures Final Listing Approval Post-Amalgamation
4,19,22,416 new equity shares will start trading on July 28, 2026.
Reader Takeaway: Regulatory approval is secured; new shares from merger are now tradable.
What just happened
Torrent Pharmaceuticals Ltd. has received the final approval from both the National Stock Exchange (NSE) and BSE Limited to list and trade 4,19,22,416 equity shares. These shares are part of the amalgamation with J. B. Chemicals & Pharmaceuticals Limited.
Why this matters
This approval signifies the completion of the regulatory procedures for the merger. It allows the newly issued shares to be officially traded on the stock exchanges, integrating the equity base of the merged entity.
The backstory
The shares were issued to the shareholders of J. B. Chemicals & Pharmaceuticals Limited as per the Scheme of Amalgamation. The record date for this share allotment was July 17, 2026, marking the eligibility for shareholders.
What changes now
With the final listing and trading approval, the 4,19,22,416 equity shares of Torrent Pharmaceuticals, each with a face value of ₹5, will commence trading on the NSE and BSE effective July 28, 2026.
Risks to watch
This is a procedural update; no new financial or operational information is provided. Investors should monitor the market performance of the newly listed shares post-commencement of trading.
Peer comparison
Merger and acquisition activities in the pharmaceutical sector often lead to such listing and trading approvals. Companies like Dr. Reddy's Laboratories and Sun Pharmaceutical Industries have undergone similar integration processes in the past.
Context metrics (time-bound)
- Shares Listed: 4,19,22,416 equity shares
- Face Value: ₹ 5 per share
- Record Date: July 17, 2026
- Commencement of Trading: July 28, 2026
What to track next
Investors should closely follow Torrent Pharmaceuticals' future financial results and operational updates to understand the impact of the amalgamation on the company's performance.